| | | Pieris (PIRS) off some premarket following earnings, as Sanofi and Roche return rights to a couple of early programs. Given how terrible the antibiotics field is, the return of the p. aeruginosa program by Sanofi shouldn't be a huge surprise. The return by Roche is of an I-O program against an undisclosed target. I doubt either event is any indictment of the technology, and other, more mature programs remain on track (though I'm still bearish on the hepcidin program). Given current burn, and allowing for some increase, they have a solid two years of cash. No position at present, but I've been watching, and am tempted to write some puts at this level.
Edit: Wrote some puts just now.
Cheers, Tuck |
|
